Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alacizumab Pegol Plus Chemotherapy in Advanced Non-Squamous NSCLC
NCT00152477Phase 2Completed
- Sponsor
- UCB
- Start
- Aug 2005
- Primary completion
- Jun 2009
- Modality
- Antibody Fragments
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of alacizumab pegol in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (3 arms), sponsored by UCB. Primary endpoint: Tumor Response Rate at 24 weeks. Started Aug 2005; status: completed.
02
Drugs
alacizumab pegol
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00152477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152477.